Radiopharm Theranostics Ltd has released a press release.
RAD 301 shows strong imaging potential in pancreatic cancer
Filed with ASX ·
6ix hasn’t read this filing yet.
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- RAD increases ownership in Radiopharm Ventures to 75%
- FDA IND approval for Phase 2b trial in brain metastases
- First patient dosed in Phase 1 therapeutic lung cancer trial
- Reinstatement to Quotation
- Radiopharm Theranostics completes A$70 million placement
Later from Radiopharm Theranostics
- Approval received to expand RAD204 Phase 1 trial
- Completion of preclinical data package for RAD 402
- Response to ASX Aware Letter
- RAD 202 receives approval to start Phase 1 therapeutic trial
- Strategic Co-Development Partnership with Lantheus for Aus
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics